AviadoBio

Focus: AviadoBio is a UK-based public biotech company focused on gene therapies for neurodegenerative diseases, particularly in oncology and neurology. The company operates at an early clinical stage with a lean, emerging portfolio.

Oncology Neurology

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About AviadoBio

AI assessmentNot Hiring

No open roles listed right now. Follow AviadoBio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AVB-101

Frontotemporal Dementia

Phase 1/2

Clinical Trials (1)

NCT06064890A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Phase 1/2

Help build intelligence for AviadoBio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to cutting-edge gene therapy science in high-unmet-need neurodegenerative diseases like frontotemporal dementia
Public company status provides potential equity upside and regulatory transparency absent in early-stage private firms
Small, early-stage team structure allows significant individual impact on pipeline development and strategic direction

Watch Out For

Only 1 active clinical trial (AVB-101 in Phase 1/2) indicates minimal near-term revenue catalysts and extended timelines to value creation
Minimal active hiring (2 total roles visible) suggests limited growth trajectory or tight capital constraints; HR and Legal focus suggests operational consolidation rather than expansion
No published research output, no disclosed financials, and sparse public data make it difficult to assess scientific credibility, cash runway, or competitive moat

Generated by Claude from AviadoBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles